SCHEMBL806148

SCHEMBL806148

COc1ccc2sc(S(=O)(=O)O)c(C)c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.47
TDP1 Q9NUW8 2/20 0.47
KDM4E B2RXH2 1/20 0.47
NPC1 O15118 1/20 0.47
ALDH1A1 P00352 1/20 0.47
MAPT P10636 1/20 0.47
RAB9A P51151 1/20 0.47
ICAM1 P05362 2/20 0.43
SELE P16581 2/20 0.43
VCAM1 P19320 1/20 0.43
BACE1 P56817 1/20 0.42
CA2 P00918 2/20 0.42
CMA1 P23946 4/20 0.42
CDK1 P06493 1/20 0.41
MAPKAPK2 P49137 1/20 0.41
PFKFB3 Q16875 3/20 0.40
PFKFB4 Q16877 3/20 0.40
MC4R P32245 1/20 0.40
NTSR1 P30989 1/20 0.40
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL788255 0.98 L3MBTL1 (0.46) L3MBTL1TDP1KDM4ENPC1ALDH1A1
SCHEMBL14620655 0.86 L3MBTL1 (0.48) L3MBTL1TDP1KDM4ENPC1ALDH1A1
SCHEMBL787547 0.85 L3MBTL1 (0.50) L3MBTL1TDP1KDM4ENPC1ALDH1A1
Potassium Ion SCHEMBL788254 0.84 L3MBTL1 (0.46) L3MBTL1TDP1KDM4ENPC1ALDH1A1
SCHEMBL787942 0.78 CMA1 (0.51) L3MBTL1CMA1PFKFB3PFKFB4NPSR1
SCHEMBL2226181 0.78 NPSR1 (0.60) L3MBTL1MAPTCMA1PFKFB3PFKFB4
SCHEMBL3946161 0.78 PFKFB3 (0.53) L3MBTL1CMA1PFKFB3PFKFB4NPSR1
Hydrochloric Acid SCHEMBL6712744 0.77 NPSR1 (0.59) L3MBTL1MAPTCMA1PFKFB3PFKFB4
SCHEMBL787895 0.76 PFKFB3 (0.57) L3MBTL1KDM4ECMA1PFKFB3PFKFB4
SCHEMBL14409805 0.75 KDM4E (0.51) L3MBTL1TDP1KDM4ENPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2616450-B1 SULFONAMIDE COMPOUNDS KANCERA AB (SE) 2018-05-02 EP disclosed
US-9233946-B2 Sulfonamide compounds KANCERA AB (SE) 2016-01-12 US disclosed
US-9233946-B2 Sulfonamide compounds KANCERA AB (SE) 2016-01-12 US disclosed
US-20130172339-A1 SULFONAMIDE COMPOUNDS KANCERA AB (SE) 2013-07-04 US disclosed
US-20130172339-A1 SULFONAMIDE COMPOUNDS KANCERA AB (SE) 2013-07-04 US disclosed
WO-2012035171-A2 NEW COMPOUNDS KANCERA AB (SE) 2012-03-22 WO disclosed
WO-2011161201-A1 BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2011-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172339-A1 SULFONAMIDE COMPOUNDS SULT1A1, STS, ARSA L3MBTL1 2627/4885TDP1 3961/4885KDM4E 2543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.